On 7 July 2026, Celltrion announced that it has successfully secured formulary listings for Vegzelma™, biosimilar to Roche/Genentech’s Avastin® (bevacizumab), with two major pharmacy benefit managers (PBMs) in the US.
Vegzelma™ was listed as a preferred drug on the government and commercial insurance formularies of Express Scripts (ESI) and on the government insurance formulary of Optum. Reimbursement coverage for ESI and Optum’s government insurances came into effect on 1 July 2026, with coverage for ESI’s commercial insurance expected to come into effect in January 2027.
Vegzelma™ was approved by the FDA in September 2022. According to Celltrion’s announcement, as of May 2026, Vegzelma™ had captured over 10% market share of the US bevacizumab sector through the open market, and it has now “secured coverage across more than 35% of the US insurance market” through the PBM formulary listings.
There are currently five other bevacizumab biosimilars approved in the US: Amgen’s Mvasi® (September 2017), Pfizer’s Zirabev® (June 2019), Amneal’s Alymsys® (April 2022), Bio-Thera/Sandoz’s Avzivi® (December 2023) and Biocon Biologics’ Jobevne™ (April 2025). More recently, on 13 January 2026, Shanghai Henlius Biotech announced that a Biologics Licence Application for its bevacizumab biosimilar, HLX04, was accepted for review by the FDA.